Highlights of weekly biotech stock moves

Active Biotech AB (SSE:ACTI) gained SEK9.70 (24%) to SEK49.40 on Thursday after partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) said it plans to submit an MAA to EMA in 2H12 for laquinimod in multiple sclerosis (MS).

The companies also reported additional data from the Phase III ALLEGRO trial showing that oral laquinimod met the secondary endpoints of reducing the mean cumulative number of gadolinium-enhancing lesions and new or enlarging T2 brain lesions as measured by MRI at 12 and 24 months (see B15)...